Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 10 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

60%

6 trials in Phase 3/4

Results Transparency

33%

3 of 9 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 3

6(75.0%)

Phase 2

2(25.0%)

8Total

Phase 3(6)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT02748460Completed

Non-interventional Study to Evaluate Long Term Safety, Prescription Management Patterns of Esmya in a Long Term Setting

Role: lead

NCT01629563Phase 3Completed

PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata

Role: lead

NCT01156857Phase 3Completed

PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata

Role: lead

NCT01252069Phase 3Completed

PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata (PEARLIII-extension Study)

Role: lead

NCT01642472Phase 3Completed

PGL4001 Efficacy Assessment in Reduction of Symptoms Due to Uterine Leiomyomata

Role: lead

NCT01635452Unknown

A Prospective Multicenter Non-interventional Study of Women Treated With ESMYA (Ulipristal Acetate) as Pre-operative Treatment of Moderate to Severe Symptoms of Uterine Fibroids

Role: lead

NCT01630252Phase 2Completed

PGL5001 Proof of Concept Study in Inflammatory Endometriosis

Role: lead

NCT01631981Phase 2Completed

PGL2001 Proof of Concept Study in Symptomatic Endometriosis

Role: lead

NCT00740831Phase 3Completed

PGL4001 Versus GnRH-agonist in Uterine Myomas

Role: lead

NCT00755755Phase 3Completed

PGL4001 Versus Placebo in Uterine Myomas

Role: lead

All 10 trials loaded